Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure

Hypertension

Volumn 55, Issue 6, 2010, Pages 1366-1372

  Van Der Zwan, Leonard P ^a   Scheffer, Peter G ^a   Dekker, Jacqueline M ^a   Stehouwer, Coen D A ^b   Heine, Robert J ^a   Teerlink, Tom ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Diabetes; Hypertension; Inflammation; Nitric oxide; Oxidized LDL

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN;

AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG USE; ELDERLY CARE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; LINEAR MODELS; MALE; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PEROXIDASE; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 77952951863     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.147231     Document Type: Article

References (34)

1. Li JJ, Fang CH, Hui RT. Is hypertension an inflammatory disease? Med Hypotheses. 2005;64:236-240.
2. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. 2005;77: 598-625.
3. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:1102-1111.
4. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595-1604.
5. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, Simoons ML, Hamm CW. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108: 1440-1445.
6. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Winterbourn CC. Plasma concentrations of myeloper-oxidase predict mortality after myocardial infarction. J Am Coll Cardiol. 2007;49:1993-2000.
7. Meuwese MC, Stroes ES, Hazen SL, Van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;50: 159-165. (Pubitemid 47002189)
8. Ali Z, Sarcia P, Mosley TH Jr, Kondragunta V, Kullo IJ. Association of serum myeloperoxidase with the ankle-brachial index and peripheral arterial disease. Vasc Med. 2009;14:215-220.
9. Schindhelm RK, Van der Zwan LP, Teerlink T, Scheffer PG. Myeloper-oxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem. 2009;55:1462-1470.
10. Zhang C, Yang J, Jennings LK. Leukocyte-derived myeloperoxidase amplifies high-glucose-induced endothelial dysfunction through interaction with high-glucose-stimulated, vascular non-leukocyte-derived reactive oxygen species. Diabetes. 2004;53:2950-2959.
11. Mooy JM, Grootenhuis PA, De Vries H, Valkenburg HA, Bouter LM, Kostense PJ, Heine RJ. Prevalence and determinants of glucose intolerance in a Dutch Caucasian population: the Hoorn Study. Diabetes Care. 1995;18:1270-1273.
12. Spijkerman AM, Adriaanse MC, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ. Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile. Diabetes Care. 2002;25:1784-1789.
13. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553.
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42: 1206-1252. (Pubitemid 37553153)
15. Scheffer PG, Van der Zwan LP, Schindhelm RK, Vermue HPA, Teerlink T. Myeloperoxidase concentrations in EDTA-plasma of healthy subjects are discordant with concentrations in heparin-plasma and serum. Clin Biochem. 2009;42:1490-1492.
16. Grooteman MP, Gritters M, Wauters IM, Schalkwijk CG, Stam F, Twisk J, Ter Wee PM, Nube MJ. Patient characteristics rather than the type of dialyser predict the variability of endothelial derived surface molecules in chronic haemodialysis patients. Nephrol Dial Transplant. 2005;20:2751-2758.
17. Van der Zwan LP, Teerlink T, Dekker JM, Henry RMA, Stehouwer CDA, Jakobs C, Heine RJ, Scheffer PG. Circulating oxidized LDL: determinants and association with brachial flow-mediated dilation. J Lipid Res. 2009;50:342-349.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc. 2001;285: 2486-2497.
19. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual for Electrocardiographic Findings: Standards and Procedures for Measurement and Classification. Boston, Mass: J Wright; 1982.
20. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem. 2000;275:37524-37532.
21. Baldus S, Heitzer T, Eiserich JP, Lau D, Mollnau H, Ortak M, Petri S, Goldmann B, Duchstein HJ, Berger J, Helmchen U, Freeman BA, Meinertz T, Münzel T. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic Biol Med. 2004; 37:902-911.
22. Yang J, Ji R, Cheng Y, Sun JZ, Jennings LK, Zhang C. L-Arginine chlorination results in the formation of a nonselective nitric-oxide synthase inhibitor. J Pharmacol Exp Ther. 2006;318:1044-1049.
23. Xu J, Xie Z, Reece R, Pimental D, Zou MH. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler Thromb Vasc Biol. 2006;26:2688-2695.
24. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation. 2002;105:1656-1662.
25. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58:342-374.
26. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
27. Keaney JF Jr, Larson MG, Vasan RS, Wilson PWF, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23:434-439.
28. King DE, Egan BM, Mainous AG, III, Geesey ME. Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens (Greenwich). 2004;6:562-568.
29. Lakoski SG, Cushman M, Palmas W, Blumenthal R, D'Agostino RB Jr, Herrington DM. The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2005;46:1869-1874.
30. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. J Am Med Assoc. 2003;290:2945-2951.
31. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001;19:857-861.
32. Singh U, Devaraj S, Jialal I. C-reactive protein stimulates myeloper-oxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin Chem. 2009;55:361-364.
33. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL. Association between myeloperoxidase levels and risk of coronary artery disease. J Am Med Assoc. 2001;286: 2136-2142.
34. Malle E, Furtmuller PG, Sattler W, Obinger C. Myeloperoxidase: a target for new drug development? Br J Pharmacol. 2007;152:838-854.